Navigation Links
Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’

GODMANCHESTER, England - (5 June 2007) - Phytopharm plc (LSE: PYM) ("Phytopharm" or the "Company") announces today pre-clinical data showing that Cogane(tm) reverses the changes in the area of the brain involved in Parkinson's disease. This data will be presented by Dr Jonathan Brotchie, an internationally recognised expert on Parkinson's disease at 'The 11th International Congress of Parkinson's Disease and Movement Disorders' 5 June in Istanbul, Turkey and published in The Movement Disorders Society's journal*.

Cogane(tm) reverses the changes in area of the brain involved in Parkinson's disease by inducing the production of neurotrophic factors. These growth factors promote the growth and connectivity of neurones and reverse the atrophy of this area of the brain. This latest study was partly funded by The Cure Parkinson's Trust.

Commenting, Tom Isaacs, co-founder of The Cure Parkinson's Trust said: "Cogane's ability to induce a person's own neurotrophic activity offers a very real prospect of a better treatment for Parkinson's disease. As a patient led organisation, The Cure Parkinson's Trust is very excited about the potential of this product to completely restore motor function to those with the condition. We are delighted our targeted fund allocation in this area of research has been directly involved in these latest findings."

Commenting, Dr Daryl Rees, Chief Executive Officer of Phytopharm, said: "There is an urgent need for new therapeutic approaches to Parkinson's disease. Pre-clinical studies with Cogane(tm), an orally bioavailable neurotrophic factor inducer, have been highly encouraging in reversing the changes in the area of the brain involved in Parkinson's disease, providing hope that Cogane(tm) could restore normal control of movement."

-Ends-


Notes to Editors

Phytopharm plc

Phytopharm is a pharmaceutical development and functi
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- ... to 2020″, provides key market data ... devices market. The report provides value, ... volume (in units) within market categories ... Sigmoidoscopes, Esophagoscopes & Gastroscopes, Duodenoscopes, Laparoscopes, ...
(Date:9/19/2014)... Sept. 19, 2014  For Cloud Pharmaceuticals, Inc., ... and development, partnering is an integral part of ... design new drugs and identify early stage, preclinical, ... further their development. The company also partners with ... this business model, Cloud Pharmaceuticals will be participating ...
(Date:9/19/2014)... Mich. , Sept. 19, 2014  Diplomat, the ... of David Dreyer to the Board of ... independent director and will also serve as chair of ... almost 30 years of accounting, financial, compliance and operating ... Mr. Dreyer has served as chief financial officer, chief ...
Breaking Medicine Technology:United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2David Dreyer Appointed to Diplomat Board of Directors 2
... 2011 Virtual Radiologic (vRad), a technology-enabled national ... PACS alternative solution, has been selected by Abbeville ... in upstate South Carolina. AAMC ... to traditional on-premise PACS that was developed by ...
... 2011 Reportlinker.com announces that a new ... catalogue: Medical Devices - ... This package contains 15 medical ... countries: Azerbaijan, China, India, Indonesia, Iran, Japan, ...
Cached Medicine Technology:vRad Selected by Abbeville Area Medical Center for PACS Replacement 2vRad Selected by Abbeville Area Medical Center for PACS Replacement 3Medical Devices - Asia 2
(Date:9/19/2014)... On September 16, Camino Public Relations ... and Top Places to Work in PR Awards Luncheon ... received honorable mentions in two categories for “Multicultural Campaign” ... elevating Latina voices in the media. , "We're honored ... part of its efforts to improve the national conversation ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Hastings and Hastings, ... years in the industry, announces a record number of visitors ... a wide variety of serious injury cases as well as ... with dog bite related accident cases and others. Having served ... Hastings has stood the test of time when it comes ...
(Date:9/19/2014)... 19, 2014 Visiting Nurse Association (VNA) ... health care, hospice and palliative care and community-based care, ... Opening Bell yesterday at the New York Stock Exchange. ... and social entrepreneur to care for immigrant families suffering ... always worked to meet the urgent healthcare needs of ...
(Date:9/19/2014)... York, New York (PRWEB) September 19, 2014 ... in a transvaginal mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) ... state court next month, Bernstein Liebhard LLP reports. ... in Dallas District Court, the company asserts that claims ... the Texas Civil Practice and Remedies Code, a section ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- Your brain structure could help ... new study suggests. Researchers at Yale University found those ... as the parietal cortex may be more likely to engage ... area. , , The study, funded by the U.S. National ... and women living in the Northeast. The researchers sought to ...
Breaking Medicine News(10 mins):Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Brain Structure Might Help Predict Risky Behavior 2
... Anchorage-independent Assay for Screening Compounds for Inhibition of ... Inc. announced today that it has received U.S. ... Cancer BioChip System (CBCS) for the identification and ... in vitro setting with great clinical ...
... combination therapy of daily consensus interferon (CIFN) and ribavirin is ... do not respond to standard therapy. The treatment works particularly ... to a new study in the June issue of ... on behalf of the American Association for the Study of ...
... people are pulling back on cosmetic procedures during the recession, ... laser vein removal . Unfortunately, most people who ... realize that beautiful, healthy legs are within their budget since ... varicose veins removed promptly, individuals are at ...
... Teel as President of Premier Anesthesia, a national anesthesia management company ... ... May 28, 2009 -- Jackson Healthcare announces the appointment ... management company based in Atlanta, Georgia., , , , ,"Having been ...
... took a major step forward to save lives and ... $1 per pack surcharge into law. Additionally, the governor ... smoking cessation services for Floridians, including monies for the ... fourth lowest in the nation. When the surcharge goes ...
... the Sisters of Charity Health System continues its strategic ... commitment to growing its physician collaboration strategies. Key to ... Jr. in the new position of senior vice president ... position May 28. "As we move through this transition ...
Cached Medicine News:Health News:Falcon Genomics Awarded Patent for Innovative Cancer Test 2Health News:New treatment option for patients with chronic hepatitis C 2Health News:Get Sexy Summer Legs From Renaissance Laser and Vein Institute (laserandveinclinic.com) Courtesy of Your Health Insurance 2Health News:Kerry Teel Named President of Premier Anesthesia 2Health News:Kerry Teel Named President of Premier Anesthesia 3Health News:Florida's $1 Cigarette Tax Increase a Big Win for Public Health 2Health News:Florida's $1 Cigarette Tax Increase a Big Win for Public Health 3Health News:Sisters of Charity Health System Appoints Orlando L. Alvarez Jr. to Head Physician Strategy and Business Development 2Health News:Sisters of Charity Health System Appoints Orlando L. Alvarez Jr. to Head Physician Strategy and Business Development 3
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Detection of Lupus Anticoagulants. Freeze-dried hexagonal phase phos-phatidylethanolamine; normal plasma with heparin inhibitor; PTT-LS reagent of cephalin and particulate siliceous activator;all fre...
... Protein C Activity by STA© ... of Protein C; highly purified ... venom for specific activation of ... activator selected specially for protein ...
Immuno-turbidimetric Assay for Protein S Antigen. Suspension of microlatex particles coated with specific antibodies....
Medicine Products: